Our study, demonstrating a reduction in Sox18 expression upon Sm4 treatment in both HDLEC and MO‐LAS, suggests that SOX18 serves as a potential therapeutic target in regulating lymphangiosarcoma and cancer‐induced lymphatic metastasis biology. Here, SOX18 is linked to lymphangiosarcoma.